Nov. 2 at 2:36 AM
$STOK "Heads up alert! Only three days until Upcoming earnings on Tuesday, 11/4/2025 for
$STOK
Bullish (8.2)
Stoke Therapeutics, Inc.
(STOK) has demonstrated significant momentum in recent months, reflected by a year-to-date stock price increase of over 200%.
The company’s lead investigational medicine, zorevunersen, shows promise as a potential first-in-class treatment for Dravet syndrome, supported by compelling data indicating sustained improvements in cognition and behavior among patients.
This is particularly notable given the contrasting results seen in natural history controls.
Analysts have reacted positively, with H.C.
Wainwright maintaining a Buy rating and a price target of
$35, underscoring the potential of zorevunersen.
Financial metrics reveal that STOK has a P/E ratio that is competitive within the biotech sector, alongside a robust earnings per share (EPS) growth trajectory.
Revenue forecasts are optimistic, driven by the anticipated approval and market entry of zorevunersen, placing the company favorably against its industry peers.
As for upcoming earnings reports, expectations are high for Stoke Therapeutics, with analysts projecting continued revenue growth fueled by zorevunersen's clinical advancements.
Historical performance has shown a consistent upward trend in market confidence, as evidenced by recent stock price surges following positive clinical data presentations.
Analyst consensus estimates suggest that the company may report earnings that exceed prior expectations, which could further bolster investor sentiment and stock performance.
Overall, the biotechnology sector is currently experiencing a favorable environment, with increased investment flowing into innovative companies like Stoke Therapeutics.
The sector's performance has been buoyed by advancements in RNA medicine and gene therapies, aligning with Stoke's strategic focus.
This positive backdrop enhances the potential for STOK's continued growth and investor interest, making it a stock to watch closely in the coming quarters.
- Funds were net buyers of
$STOK during the previous reporting quarter.
- Funds with large holdings in
$STOK include:
- RTW Investments LP, MV:
$58MM. Fund Rank: 74%
www.rtwfunds.com
- Baker Brothers Advisors LP, MV:
$53MM. Fund Rank: 71%
- Redmile Group LLC, MV:
$50MM. Fund Rank: 55%
www.redmilegroup.com
- Opaleye Management, MV:
$6MM. Fund Rank: 82%
- Granahan Investment Management Inc, MV:
$6MM. Fund Rank: 59%
www.granahan.com
- Last 10 days performance: -8%
- Last 30 days performance: 21%
- Last 90 days performance: 133%
Some of the latest news articles:
- Title: Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
Publication Date: 10/30/2025 8:30:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/stoke-therapeutics-host-webcast-conference-203000835.html?.tsrc=rss
- Title: Stoke Therapeutics (STOK): Exploring Valuation After a 2% Monthly Gain and 200% YTD Growth
Publication Date: 10/21/2025 9:11:59 PM, Source: yahoo
URL: https://finance.yahoo.com/news/stoke-therapeutics-stok-exploring-valuation-211159407.html?.tsrc=rss
- Title: Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
Publication Date: 10/20/2025 11:30:00 AM, Source: yahoo
URL: https://finance.yahoo.com/news/stoke-therapeutics-presents-two-natural-113000751.html?.tsrc=rss
- Title: H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK)
Publication Date: 10/19/2025 7:09:24 AM, Source: yahoo
URL: https://finance.yahoo.com/news/h-c-wainwright-maintains-buy-070924351.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
